{"id":65704,"date":"2026-05-19T23:08:31","date_gmt":"2026-05-19T15:08:31","guid":{"rendered":"https:\/\/flcube.com\/?p=65704"},"modified":"2026-05-19T23:08:33","modified_gmt":"2026-05-19T15:08:33","slug":"regeneron-partners-with-parabilis-medicines-on-2-2b-helicon-peptide-platform-deal-targeting-undruggable-proteins","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65704","title":{"rendered":"Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting &#8220;Undruggable&#8221; Proteins"},"content":{"rendered":"\n<p><strong>Regeneron Pharmaceuticals, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/REGN:NASDAQ\">NASDAQ: REGN<\/a>) announced a <strong>strategic research collaboration<\/strong> with <strong>Parabilis Medicines<\/strong> to discover and develop <strong>multiple therapeutic candidates<\/strong> leveraging Parabilis&#8217; proprietary <strong>Helicon peptide platform<\/strong>. The partnership focuses on <strong>Antibody-Helicon Conjugates (AHCs)<\/strong>, a novel therapeutic class designed to target <strong>historically &#8220;undruggable&#8221; intracellular protein targets<\/strong>, with Regeneron committing <strong>$125 million upfront<\/strong> and potential <strong>$2.2 billion in milestone payments<\/strong> across five initial targets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-financial-terms\">Deal Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>$50 million<\/td><td>Cash payment to Parabilis upon closing<\/td><\/tr><tr><td><strong>Equity Investment<\/strong><\/td><td>$75 million<\/td><td>Commitment to invest in Parabilis&#8217; next financing round<\/td><\/tr><tr><td><strong>Total Initial Commitment<\/strong><\/td><td>$125 million<\/td><td>Subject to certain closing conditions<\/td><\/tr><tr><td><strong>Development Milestones<\/strong><\/td><td>Up to $2.2 billion<\/td><td>Across five initial targets for development, regulatory, and commercial achievements<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Low double-digits<\/td><td>Tiered royalties on net sales of approved medicines<\/td><\/tr><tr><td><strong>Additional Targets<\/strong><\/td><td>Option-based<\/td><td>Regeneron may pursue more targets with additional option payments<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-innovation\">Technology Platform Innovation<\/h2>\n\n\n\n<p><strong>Parabilis&#8217; Helicon platform<\/strong> represents a breakthrough approach to targeting previously inaccessible proteins:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Helicon Peptides<\/strong>: <strong>Stabilized, cell-penetrant alpha-helical peptides<\/strong> engineered to engage intracellular targets<\/li>\n\n\n\n<li><strong>Target Scope<\/strong>: Designed to bind <strong>flat protein surfaces<\/strong> not amenable to traditional small molecule binding<\/li>\n\n\n\n<li><strong>Therapeutic Formats<\/strong>: Development of both <strong>stand-alone Helicon therapies<\/strong> and <strong>Antibody-Helicon Conjugates (AHCs)<\/strong><\/li>\n\n\n\n<li><strong>&#8220;Undruggable&#8221; Focus<\/strong>: Addresses approximately <strong>85% of human proteins<\/strong> historically considered undruggable with conventional modalities<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-for-regeneron\">Strategic Rationale for Regeneron<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Diversification<\/strong>: Expands Regeneron&#8217;s technology portfolio beyond antibodies into <strong>next-generation peptide therapeutics<\/strong><\/li>\n\n\n\n<li><strong>Target Expansion<\/strong>: Enables pursuit of <strong>high-value intracellular targets<\/strong> previously inaccessible to Regeneron&#8217;s antibody platform<\/li>\n\n\n\n<li><strong>Innovation Leadership<\/strong>: Positions Regeneron at forefront of <strong>convergent therapeutic modalities<\/strong> combining antibodies with cell-penetrant peptides<\/li>\n\n\n\n<li><strong>Pipeline Enhancement<\/strong>: Five initial targets provide multiple shots on goal with substantial milestone upside<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Undruggable Target Market<\/strong>: Represents <strong>trillion-dollar opportunity<\/strong> across oncology, neurology, and rare diseases<\/li>\n\n\n\n<li><strong>Peptide Therapeutics Growth<\/strong>: Global peptide market projected to reach <strong>$56 billion by 2030<\/strong>, with stabilized peptides capturing premium segments<\/li>\n\n\n\n<li><strong>Conjugate Innovation<\/strong>: AHCs represent evolution beyond traditional ADCs, enabling <strong>intracellular target engagement<\/strong><\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Regeneron&#8217;s substantial commitment validates Parabilis&#8217; technology as <strong>best-in-class<\/strong> among emerging peptide platforms<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-parabilis-medicines-strategic-position\">Parabilis Medicines Strategic Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capital Infusion<\/strong>: $125 million provides <strong>non-dilutive funding<\/strong> plus equity investment to advance internal pipeline<\/li>\n\n\n\n<li><strong>Validation Premium<\/strong>: Regeneron partnership establishes <strong>market validation<\/strong> for Helicon platform technology<\/li>\n\n\n\n<li><strong>Resource Leverage<\/strong>: Access to Regeneron&#8217;s <strong>world-class discovery and development capabilities<\/strong><\/li>\n\n\n\n<li><strong>Future Flexibility<\/strong>: Retains rights to additional targets beyond the initial five-program collaboration<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-strategy-amp-timeline\">Development Strategy &amp; Timeline<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Initial Focus<\/strong>: Five high-priority targets selected for their <strong>therapeutic potential<\/strong> and <strong>technical feasibility<\/strong><\/li>\n\n\n\n<li><strong>Dual Modality Approach<\/strong>: Parallel development of <strong>stand-alone Helicons<\/strong> and <strong>AHC formats<\/strong> to maximize success probability<\/li>\n\n\n\n<li><strong>Milestone Structure<\/strong>: Payments tied to <strong>clear development inflection points<\/strong>, de-risking Regeneron&#8217;s investment<\/li>\n\n\n\n<li><strong>Expansion Options<\/strong>: Framework allows <strong>scalable collaboration<\/strong> based on initial program success<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-advantages\">Competitive Advantages<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Differentiation<\/strong>: Ability to address <strong>protein-protein interactions<\/strong> and <strong>flat binding surfaces<\/strong> inaccessible to small molecules<\/li>\n\n\n\n<li><strong>Cellular Penetration<\/strong>: Engineered helical peptides overcome traditional <strong>cell membrane barriers<\/strong><\/li>\n\n\n\n<li><strong>Conjugate Precision<\/strong>: AHCs combine <strong>antibody targeting specificity<\/strong> with <strong>intracellular peptide activity<\/strong><\/li>\n\n\n\n<li><strong>Platform Scalability<\/strong>: Modular design enables rapid development against multiple target classes<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-investment-implications\">Investment Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Risk-Reward Profile<\/strong>: Substantial milestone payments reflect <strong>high-value targets<\/strong> with blockbuster potential<\/li>\n\n\n\n<li><strong>Platform Optionality<\/strong>: Success with initial targets could trigger <strong>additional target selections<\/strong> and expanded collaboration<\/li>\n\n\n\n<li><strong>Market Timing<\/strong>: Partnership coincides with increasing investor interest in <strong>next-generation therapeutic platforms<\/strong><\/li>\n\n\n\n<li><strong>Strategic Moats<\/strong>: Proprietary stabilization technology creates <strong>sustainable competitive advantages<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the collaboration&#8217;s implementation, development timelines, and financial implications. Actual results may differ due to risks including technical feasibility challenges, development delays, competitive dynamics, and regulatory outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a strategic research collaboration with Parabilis Medicines to discover&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,1166,1426],"class_list":["post-65704","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-nasdaq-regn","tag-regeneron-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting &quot;Undruggable&quot; Proteins - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates leveraging Parabilis&#039; proprietary Helicon peptide platform. The partnership focuses on Antibody-Helicon Conjugates (AHCs), a novel therapeutic class designed to target historically &quot;undruggable&quot; intracellular protein targets, with Regeneron committing $125 million upfront and potential $2.2 billion in milestone payments across five initial targets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65704\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting &quot;Undruggable&quot; Proteins\" \/>\n<meta property=\"og:description\" content=\"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates leveraging Parabilis&#039; proprietary Helicon peptide platform. The partnership focuses on Antibody-Helicon Conjugates (AHCs), a novel therapeutic class designed to target historically &quot;undruggable&quot; intracellular protein targets, with Regeneron committing $125 million upfront and potential $2.2 billion in milestone payments across five initial targets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65704\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-19T15:08:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-19T15:08:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65704#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65704\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting &#8220;Undruggable&#8221; Proteins\",\"datePublished\":\"2026-05-19T15:08:31+00:00\",\"dateModified\":\"2026-05-19T15:08:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65704\"},\"wordCount\":580,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"NASDAQ: REGN\",\"Regeneron Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65704#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65704\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65704\",\"name\":\"Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting \\\"Undruggable\\\" Proteins - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-19T15:08:31+00:00\",\"dateModified\":\"2026-05-19T15:08:33+00:00\",\"description\":\"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates leveraging Parabilis' proprietary Helicon peptide platform. The partnership focuses on Antibody-Helicon Conjugates (AHCs), a novel therapeutic class designed to target historically \\\"undruggable\\\" intracellular protein targets, with Regeneron committing $125 million upfront and potential $2.2 billion in milestone payments across five initial targets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65704#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65704\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65704#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting &#8220;Undruggable&#8221; Proteins\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting \"Undruggable\" Proteins - Insight, China&#039;s Pharmaceutical Industry","description":"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates leveraging Parabilis' proprietary Helicon peptide platform. The partnership focuses on Antibody-Helicon Conjugates (AHCs), a novel therapeutic class designed to target historically \"undruggable\" intracellular protein targets, with Regeneron committing $125 million upfront and potential $2.2 billion in milestone payments across five initial targets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65704","og_locale":"en_US","og_type":"article","og_title":"Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting \"Undruggable\" Proteins","og_description":"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates leveraging Parabilis' proprietary Helicon peptide platform. The partnership focuses on Antibody-Helicon Conjugates (AHCs), a novel therapeutic class designed to target historically \"undruggable\" intracellular protein targets, with Regeneron committing $125 million upfront and potential $2.2 billion in milestone payments across five initial targets.","og_url":"https:\/\/flcube.com\/?p=65704","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-19T15:08:31+00:00","article_modified_time":"2026-05-19T15:08:33+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65704#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65704"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting &#8220;Undruggable&#8221; Proteins","datePublished":"2026-05-19T15:08:31+00:00","dateModified":"2026-05-19T15:08:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65704"},"wordCount":580,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","NASDAQ: REGN","Regeneron Pharmaceuticals"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65704#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65704","url":"https:\/\/flcube.com\/?p=65704","name":"Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting \"Undruggable\" Proteins - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-19T15:08:31+00:00","dateModified":"2026-05-19T15:08:33+00:00","description":"Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a strategic research collaboration with Parabilis Medicines to discover and develop multiple therapeutic candidates leveraging Parabilis' proprietary Helicon peptide platform. The partnership focuses on Antibody-Helicon Conjugates (AHCs), a novel therapeutic class designed to target historically \"undruggable\" intracellular protein targets, with Regeneron committing $125 million upfront and potential $2.2 billion in milestone payments across five initial targets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65704#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65704"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65704#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting &#8220;Undruggable&#8221; Proteins"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65704"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65704\/revisions"}],"predecessor-version":[{"id":65705,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65704\/revisions\/65705"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}